Wu, C-I;
Postema, PG;
Arbelo, E;
Behr, ER;
Bezzina, CR;
Napolitano, C;
Robyns, T;
Probst, V;
Schulze-Bahr, E;
Remme, CA;
et al.
Wu, C-I; Postema, PG; Arbelo, E; Behr, ER; Bezzina, CR; Napolitano, C; Robyns, T; Probst, V; Schulze-Bahr, E; Remme, CA; Wilde, AAM
(2020)
SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes.
Heart Rhythm, 17 (9).
pp. 1456-1462.
ISSN 1556-3871
https://doi.org/10.1016/j.hrthm.2020.03.024
SGUL Authors: Behr, Elijah Raphael
Abstract
Ever since the first case was reported at the end of 2019, the SARS-COV-2 virus and associated lung disease COVID-19 has spread throughout the world and has become a pandemic. In particular, the high transmission rate of the virus has made it a threat to public health globally. Currently, there is no proven effective therapy against the virus, and the impact on other diseases is also uncertain, especially inherited arrhythmia syndrome. Arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk for cardiac arrhythmias, either secondary to acquired conditions or co-morbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as Long QT syndrome, Brugada syndrome, Short QT syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to pro-arrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances and use of antiviral drugs. We here describe the potential COVID-19 associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic.
Statistics
Item downloaded times since 06 Apr 2020.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |